Lantern Pharma (NASDAQ: LTRN) reported its second-quarter 2026 operational and financial results, showcasing significant advancements in its AI-driven oncology pipeline and the strategic establishment of Open Medicine AI (“OMAI”) as a separate company. The company’s progress includes encouraging clinical trial data, regulatory clearances, and a new commercial venture, underscoring its commitment to transforming cancer therapy development.
Emerging data from the Phase 2 HARMONIC™ trial of LP-300 demonstrated a deepening progression-free survival benefit with longer treatment duration in patients with EGFR exon 21 L858R mutations. This is particularly notable for never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment, a population with high unmet need. Additionally, the U.S. Food and Drug Administration (FDA) reviewed key protocol amendments for the trial without objection, allowing the study to proceed as planned.
In Europe, the European Medicines Agency (EMA) cleared an investigator-initiated Phase 1b/2 trial of LP-184, also known as zirdafulven, in biomarker-selected advanced bladder cancer. This approval expands the clinical development of LP-184 beyond its current focus on CNS cancers and solid tumors. The U.S. Patent and Trademark Office (USPTO) also issued a Notice of Allowance for a three-gene patient-selection signature for LP-184, strengthening the company’s intellectual property portfolio and precision medicine approach.
A major strategic move was the establishment of OMAI as a wholly owned subsidiary in August, along with board-approved commercial licensing agreements for the multi-agentic AI co-scientist platform previously launched as withZeta.ai. This platform is now available as a subscription-based research tool for the global biomedical and drug development community, representing a new revenue stream for Lantern. The spin-out of OMAI allows for focused development and commercialization of this AI platform, potentially unlocking value for shareholders.
Financially, Lantern reported a second-quarter loss from operations of approximately $3.5 million, a 25% improvement from the $4.7 million loss in the same period last year. Research and development expenses declined 42% to approximately $1.8 million, reflecting efficient capital allocation. Net loss was approximately $7.1 million, or $0.57 per share, compared with $4.3 million, or $0.40 per share, a year earlier. The increase was largely due to a $3.6 million warrant-related expense. As of June 30, 2026, the company held cash, cash equivalents, and marketable securities totaling approximately $7.4 million.
Lantern Pharma continues to leverage its proprietary RADR® platform, which uses AI and machine learning to identify patient populations most likely to benefit from its therapies. The company’s pipeline includes LP-184, LP-284 (a TC-NER targeting compound for hematologic and solid tumors), and LP-300. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, a wholly owned CNS-focused subsidiary. Lantern operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.
The establishment of OMAI and the commercial launch of withZeta.ai signal Lantern’s ambition to become a leader in AI-driven drug discovery and development. By offering its AI platform to the broader biomedical community, Lantern not only creates a new revenue stream but also positions itself at the forefront of the convergence of AI and oncology. The positive trial data and regulatory progress further validate the company’s precision medicine approach, offering hope for improved outcomes in difficult-to-treat cancers.
For more details, visit the full press release at https://nnw.fm/m9pULA.
